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Abstract
Background: The increasing use of erythropoietins with long half-lives and the tendency to lengthen the
administration interval to monthly injections call for raising awareness on the pharmacokinetics and risks of new
erythropoietin stimulating agents (ESA). Their pharmacodynamic complexity and individual variability limit the
possibility of attaining comprehensive clinical experience. In order to help physicians acquiring prescription abilities,
we have built a prescription computer model to be used both as a simulator and education tool.
Methods: The pharmacokinetic computer model was developed using Visual Basic on Excel and tested with 3
different ESA half-lives (24, 48 and 138 hours) and 2 administration intervals (weekly vs. monthly). Two groups of 25
nephrologists were exposed to the six randomised combinations of half-life and administration interval. They were
asked to achieve and maintain, as precisely as possible, the haemoglobin target of 11-12 g/dL in a simulated naïve
patient. Each simulation was repeated twice, with or without randomly generated bleeding episodes.
Results: The simulation using an ESA with a half-life of 138 hours, administered monthly, compared to the other
combinations of half-lives and administration intervals, showed an overshooting tendency (percentages of Hb
values > 13 g/dL 15.8 ± 18.3 vs. 6.9 ± 12.2; P < 0.01), which was quickly corrected with experience. The
prescription ability appeared to be optimal with a 24 hour half-life and weekly administration (ability score
indexing values in the target 1.52 ± 0.70 vs. 1.24 ± 0.37; P < 0.05). The monthly prescription interval, as suggested
in the literature, was accompanied by less therapeutic adjustments (4.9 ± 2.2 vs. 8.2 ± 4.9; P < 0.001); a direct
correlation between haemoglobin variability and number of therapy modifications was found (P < 0.01).
Conclusions: Computer-based simulations can be a useful tool for improving ESA prescription abilities among
nephrologists by raising awareness about the pharmacokinetic characteristics of the various ESAs and recognizing
the factors that influence haemoglobin variability.
Background
The recent development of long-acting erythropoietin
stimulating agents (ESA), and the clinical trend to
increase ESA administration intervals, have markedly
changed the ESA prescription profile in nephrology.
Thus, from a half-life of 19.4 ± 2.4 hours for erythro-
poietin alpha [1] and 24.2 ± 2.6 hours for erythropoietin
beta [2] after subcutaneous administration, and a recom-
mendation to administer these agents up to three times
per week, we are now using compounds such as
darbepoetin [3] -and, recently, CERA- that have a much
longer half-life (48.8 ± 5.2 hours and 139 ± 20 hours,
[4,5] respectively), with the suggestion to lengthen the
administration interval up to once monthly. However,
the correct application of the new strategies implies that
users are well aware of the pharmacological characteris-
tics and risks of the newer long-acting molecules.
Although these assumptions have probably not been
met, prescribers seem to have quickly and spontaneously
adapted to the new conditions, but numerous observations
document important - and sometimes cyclical - fluctua-
tions in the haemoglobin values of chronically-treated
patients. This has led to numerous questions, which the
current clinical, pharmacokinetic and pharmacodynamic
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knowledge has been able to answer only in part [6-18].
With respect to haemoglobin cycling in particular, the pre-
scription strategy, especially considering frequent and sud-
den adjustments in erythropoietin dosage, has been
considered a possible triggering factor [19-21], while so far
no direct effect of a longer administration interval on hae-
moglobin stability has been noted. The debate on the
causes of haemoglobin variability would be purely aca-
demic if the stability of haemoglobin were not to be within
a therapeutic margin that, in these last few years, has
become narrower, and if the haemoglobin fluctuations had
not been associated with a greater morbidity [22].
In order to help physicians acquire prescription ability,
and with the hope of reducing haemoglobin variability,
we felt it was relevant to build a pharmacokinetic com-
puter model to be used as an ESA prescription simula-
tor. The aim of this simulator is to raise awareness
among ESA users about the implications of recent
changes in erythropoietin half-life and prescription
intervals. For this purpose, we have built a simulator
that asks users to prescribe various ESAs for a naïve
patient and to adjust the dose as precisely as possible in
a 12-week equilibration or balance phase followed by a
20-week maintenance phase (haemoglobin target 11-
12 g/dL). The epoetin half-life and the interval of
administration will be assigned to the user at the start
of the exercise, while the initial haemoglobin and the
patient’s erythropoietin sensitivity are randomly gener-
ated by the software.
Although such a simulator, contrary to other models
based, for instance, on Artificial Neural Networks or
Bayesian Adaptive Control [23], is not a prediction tool
applicable to clinical practice, we feel that it could be a
good way to improve the physicians’ ability to prescribe
ESAs. Moreover, the simulator should enable us to
answer the following questions: (1) Is the ability to keep
haemoglobin within the target (primary end point) and
haemoglobin stability (secondary end point) influenced
by the erythropoietin half-life and administration inter-
val and/or by the use of the simulator (learning effect)?
(2) Does the number of changes in ESA dosing correlate
with the fluctuations in haemoglobin values and admin-
istration interval (secondary end point)? (3) Is the intra-
patient delta haemoglobin a more sensitive indicator of
haemoglobin stability compared to the standard devia-
tion (secondary end point)?
Methods
Simulator characteristics
The “epoietin prescription simulator” was developed in
Visual Basic on Excel. The version used in the study is
annexed to this document (see Additional File 1 named
The Epoetin Prescription Simulator). The user’s manual
as well as the formulae, including a mono-exponential
one that relates the erythropoietin half-life selected for
the simulation to ESA’s concentration and its effect on
the production of new red blood cells, are detailed in
the Additional File 2 named Appendix 1.
The simulator randomly defines, for an ESA naïve
patient, the starting haemoglobin (Hb), with 0.1 g/dL
increments, in a range between 7.0 and 8.0 g/dL. To
better adjust to clinical practice, it automatically
includes, for the duration of the simulation, incidental
fluctuations in Hb with an absolute magnitude
between -0.5 and +0.5 g/dL [24]. The subject’s sensitiv-
ity to epoetin is randomly assigned, making sure that
the population’s average weekly need for epoetin in
order to reach the pre-established haemoglobin target
of 11-12 g/dL [25] is at approximately 6,000 units. The
mean red blood cell (RBC) lifespan in the initial con-
figuration is always set at 61.2 days, and will fluctuate
during the simulation according to the erythrocyte age
distribution. The amount of weekly epoetin needed,
the initial RBC lifespan and the pre-erythrocyte
kinetics are simulated according to the data of the lit-
erature [26-32].
The home page contains a window with the half-life
selected for the test (restricted to 24, 48 and 138 hours),
another with the current haemoglobin, an active window
where the epoetin dosage can be entered (initially
weekly or biweekly and, after 8 weeks, weekly or
monthly as predetermined), and finally one showing the
statistics of the test in progress from the first week.
Statistics are automatically updated during the simula-
tion and summarise the following parameters: mean Hb
with SD, variability based on the delta Hb (average of
the difference between consecutive values), mean RBC
lifespan, percentage of Hb values < 11, >12 and >13 g/
dL, and a score (“ability score”) starting from 1 (meaning
that 100% of the values are outside the target range); the
score increases with the decrease of Hb values outside
the predetermined optimal range of 11-12 g/dL (a hae-
moglobin value above 13 g/dl is counted as a double
error: one point for Hb > 12 and another for Hb >
13 g/dL; see appendix 1 for details). The model also
includes the possibility of randomly adding an acute
bleeding episode with depletion of blood volume
between 0% and 30%.
Considering that the software is annexed to the
paper, we remind those users who are outside the cur-
rent study that, taking into account the simplification
of the biological process on which the design was
based, and the fact that pharmacodynamic data for
erythropoietin are incomplete and affected by signifi-
cant differences among individuals, the model cannot
be used to compare erythropoietin products currently
on the market or to prescribe erythropoietin in clinical
practice.
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Selected population and procedure
In order to meet the study’s needs, we asked two inde-
pendent groups of 25 nephrologists (both graduates or
still pursuing their degree) selected during a national-
level meeting to participate by completing the 6 predeter-
mined simulations in random order (erythropoietin with
24, 48 or 138 hours of half-life combined with weekly or
monthly administration interval). Each group’s participa-
tion was planned to be separated by nine months.
The first session was scheduled during CERA’s pre-
marketing stage and was designed to be carried out with
candidates without experience with the new molecule;
the second one was the opposite, taking place after
CERA had entered the market. In the first session
(simulation A), in order to double the number of equili-
bration events to which each candidate was subjected,
and to analyse the learning curve, an acute bleeding epi-
sode (0-30% of blood volume) was randomly introduced
into the model between weeks 18 and 24. During the
second session (simulation B) we exposed each candi-
date to the six predetermined simulations but without
acute bleeding episodes. In each simulation, candidates
were asked to enter an erythropoietin dosage, taking
into account the erythropoietin half-life and administra-
tion interval already entered with the purpose of reach-
ing as fast as possible and with the maximum precision
the Hb target (between 11 and 12 g/dL), adapting the
dosage in the following weeks/months as if it was a
patient on haemodialysis.
Statistical analysis
Statistical analyses were performed using a statistical
software package (SPSS 12.0; SPSS Inc., Chicago, IL,
USA). Results were expressed as mean ± SD. Intra-
patient [33] haemoglobin variability other than SD was
estimated from the average of the absolute value of the
differences between consecutive parameters defined in
the text “delta Hb”. The haemoglobin target was
selected with a narrow margin (11-12 g/dL) to improve
the likelihood of finding differences between the groups.
Comparisons between parameters were carried out with
a paired t-test, while Hb profiles as a function of time
were compared using a trapezoidal estimation of the
area under the curves followed by a Wilcoxon Signed
Ranks test. Percentages were compared using a Fisher
Exact test. In all cases, a P ≤ 0.05 was considered statis-
tically significant; P was expressed as ns (not significant),
0.05, <0.05, <0.01 and <0.001.
Results
The Hb course as a function of time (expressed as simu-
lation weeks) and the average Hb in each simulation
modality are shown in Figure 1 and Table 1, respectively.
In order to facilitate the comparison of the different
curves, the bleeding phases are not represented in the
graph and the curves have been synchronised. Thus,
the second equilibration phase starts on the graph in the
same week for each patient and each modality. As can be
observed, and even if the curves with the exception of
138M were not statistically different, the combination of
half-life and administration interval that, in the equilibra-
tion phase, mostly respected the target range was
24 hours with weekly administration (24W). The only
curve on Figure 1 that was significantly different from
the others (P < 0.01) was associated with overshooting:
the 138M (138 h half-life and monthly administration
interval). With this combination, and comparing with the
other simulations, the percentage of Hb values > 13 g/dL
was 15.8 ± 18.3% vs. 6.9 ± 12.2%; P < 0.01). To support a
favourable learning effect, no significant differences
between groups were observed during the equilibration
phase following the bleeding episode. In this regard, com-
paring with the first equilibration phase, the overall dis-
persion of Hb values outside the target range was
significantly smaller: average Hb dispersion in the last
8 weeks of the 2 equilibration phases 1.32 ± 0.28 vs.
0.63 ± 0.26 g/dL; P < 0.01; Hb percentage values outside
the target of 11-12 g/dL 50.0 ± 30.9 vs. 18.8 ± 28.8%; P =
0.05) (secondary end-point). Haemoglobin variability is
detailed in Table 1 using as parameters the SD and the
average of the absolute value of the difference between
consecutive measurements “delta Hb”.
Changes in Hb observed during the second simulation
(simulation B), which was carried out after the market-
ing of CERA are shown in Figure 2. As shown in the
Figure, no curves were characterized by an evident over-
shooting of (mean Hb > 13g/dL).
The comparison between monthly and weekly admin-
istration is shown in Figure 3 (where only Hb values
that were visible to the simulator user are represented)
and Figure 4 (representing the weekly haemoglobin
values for the entire simulation).
Haemoglobin variability during the maintenance phase
is represented in Figure 5, using the SD and the average
of the absolute value of the difference “delta Hb”
between consecutive measurements. The monthly
administration interval compared with the weekly one
was associated with a significantly higher delta Hb (0.76
vs. 0.34 g/dL; P < 0.01). The SD was not able to detect
the difference (secondary end-point). The same para-
meters are shown in Table 2 for the entire simulation.
Table 2 shows the percentage of values outside the
target during the 32 weeks of the simulation for each
modality, comparing monthly to weekly administration.
Monthly administration is characterised by a lower per-
centage of Hb values at the target of 11-12 g/dL (18.4
vs. 26.8%; P < 0.05), but there are also fewer values
above 12 or 13 g/dL (11.8 vs. 25.3%; P < 0.01 and 4.3
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vs. 13.0; P < 0.05). With respect to the ability score, the
only modality that stands out from the rest in a signifi-
cant way is that associating the short half-life (24 hours)
with the weekly administration (1.52 ± 0.70 vs. 1.24 ±
0.37; P < 0.05) (primary end point).
The error in determining the maintenance dose was
estimated by calculating the difference between the
mean weekly dose of erythropoietin used in the
equilibration phase and that used in the maintenance
phase (6084 ± 3057 vs. 5575 ± 1828 U/Week). The dis-
crepancy, as illustrated in Figure 6, was found to be lar-
ger for weekly than for monthly administration (14.5 ±
15.9 vs. 9.1 ± 11.0%; P < 0.05), with differences increas-
ing together with the half-life of the ESA.
Whatever the drug half-life, the weekly administration
of ESA was associated with a significantly higher num-
ber of adjustments of the doses (4.9 ± 2.2 vs. 8.2 ± 4.9;
P < 0.001). Figure 7 presents the significant direct corre-
lation between the number of therapy modifications and
haemoglobin variability, expressed as delta Hb, during
the maintenance phase (secondary end-point).
Interestingly, both the half-life of erythropoietin and
the administration interval appear to affect the age dis-
tribution of red blood cells (RBC) within the circulating
population, modifying the mean RBC lifespan. The
variability of the RBC lifespan is expressed in Figure 8
as SD. The variability decreases with an increase in the
half-life of erythropoietin and with a decrease in the
administration interval.
Table 1 Haemoglobin variability in simulation A
Mean Hb (g/dL) SD Delta Hb
24W 10.37 1.65 1.19
24M 10.55 1.59 1.26
48W 10.41 1.68 1.28
48M 10.53 1.66 1.17
138W 10.55 1.86 1.34
138M 10.76 1.88 1.39
Average Hb and variability expressed as standard deviation and delta Hb
(average of the absolute value of the difference between consecutive
measurements) for the 6 modalities. Half-life in h: 24, 48 and 138;
administration interval, weekly (W) or monthly (M). N = 25.
Figure 1 Haemoglobin course; simulation A (before CERA’s marketing). Hb as a function of the weeks elapsed since the start of the
simulation for the 6 combinations of half-lives and administration intervals (half-life in h: 24, 48 and 138; administration interval, weekly (W) or
monthly (M); 24W solid line with black triangles, 48W solid line with black squares, 138W solid line with black diamonds, 24M dotted line with
white triangles, 48M dotted line with white squares, 138M dotted line with white diamonds). The randomly-assigned bleeding phase between
the two equilibration exercises is not represented; the second equilibration phase is synchronised. N = 25.
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Figure 2 Haemoglobin course in simulation B (after CERA’s marketing). Hb as a function of the weeks elapsed since the start of the
simulation for the 6 combinations of half-lives and administration intervals (half-life in h: 24, 48 and 138; administration interval, weekly (W) or
monthly (M); 24W solid line with black triangles, 48W solid line with black squares, 138W solid line with black diamonds, 24M dotted line with
white triangles, 48M dotted line with white squares, 138M dotted line with white diamonds). To better evaluate the equilibration phase no
bleeding episodes were introduced. N = 25.
Figure 3 Monthly haemoglobin course comparing monthly and weekly administration intervals; simulation B. Monthly Hb as a function
of the weeks elapsed since the start of the simulation for the 2 administration intervals: monthly M (dotted line with white squares) or weekly
W (solid line with black squares). N = 25.
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Figure 4 Weekly haemoglobin course comparing monthly and weekly administration intervals; simulation B. Weekly Hb as a function of
the weeks elapsed since the start of the simulation for the 2 administration intervals: monthly M (dotted line with black squares) or weekly W
(solid line with black squares). The simulator user was aware of the monthly values only. N = 25.
Figure 5 Haemoglobin variability in simulation B. Hb variability expressed as standard deviation (SD) and delta Hb (absolute value of the
difference between consecutive measurements) comparing the 2 administration intervals: monthly M (black columns) and weekly W (white
columns). The difference between columns in “Delta Hb” is significant; P < 0.01. N = 25.
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Discussion
The purpose of this study was to develop a new tool to
improve the physicians’ ability to prescribe erythropoietin
stimulating agents in dialysis patients and hence to raise
awareness on the pharmacological consequences result-
ing from the use of ESAs with a very long half-life over
longer administration intervals. Our two simulations (A
and B), performed before and after CERA’s marketing,
enable us to conclude that the simulator is user-friendly
and that its use is associated with learning (less disper-
sion of Hb values and improvement of the ability to
respect the predetermined target).
Simulation modality A was tested with a group of
nephrologists who had never used erythropoietins with half-
lives longer than 48 hours, showing that the first approach
with a prolonged half-life (138 hours) and a monthly admin-
istration interval could have overshooting as a consequence.
Nevertheless, the risk of overshooting is quickly corrected
thanks to the learning, and the prescriber is already able to
avoid the administration of an excessive dose in the second
equilibration phase of the same simulation.
Interestingly, in simulation B, performed after CERA’s
marketing with a group of nephrologists being aware of
its long half-life (about 139 hours), overshooting tenden-
cies were not observed. The same simulation, compared
with the first one, allowed a more detailed analysis of
the maintenance phase following the initial equilibration
phase. Surprisingly, the simulation has shown that
Table 2 Haemoglobin values and ability score; simulation B
24M 24W 48M 48W 138M 138W M W P
Haemoglobin (g/dL) Mean 10.38 11.10 10.20 11.36 10.32 10.82 10.30 11.09 <001
SD 1.23 1.57 1.15 1.91 1.33 1.62 1.24 1.70
Delta Hb 0.82 1.01 0.70 1.33 0.85 0.98 0.79 1.11
Haemoglobin values <11 g/dL (%) 70.39 44.22 73.28 45.94 65.73 53.58 69.80 47.91 <0.001
SD 26.57 23.48 25.50 20.92 27.92 21.17 26.66 21.85
Haemoglobin values >12 g/dL (%) 12.53 23.68 8.68 30.18 14.32 21.90 11.84 25.25 <0.01
SD 17.38 24.36 14.65 20.73 20.58 19.10 17.54 21.39
Haemoglobin values >13 g/dL (%) 5.51 10.77 2.89 17.09 4.60 11.02 4.33 12.69 <0.01
SD 11.89 16.80 7.74 18.64 9.74 13.41 9.79 16.28
Ability score 1.20 1.52 1.22 1.23 1.25 1.24 1.22 1.33 ns
SD 0.33 0.70 0.23 0.57 0.31 0.34 0.29 0.54
Mean haemoglobin with SD and delta Hb, value percentages outside the target (during the 32 weeks of the simulation) and ability score for the 6 modalities,
comparing monthly to weekly administration (half-life of 24, 48 and 138 hours; monthly M and weekly W administration) (simulation B). N = 25.
Figure 6 Epoetin dose reduction, equilibration vs. maintenance in simulation B. Error in determining the maintenance dose estimated by
calculating the percentage difference between the mean erythropoietin dose used in the equilibration phase and that used in the maintenance
phase (half-life of 24, 48 and 138 h; monthly M and weekly W administration). N = 25.
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Figure 8 RBC lifespan variability in simulation B. RBC lifespan variability (expressed as standard deviation) as a function of erythropoietin half-life
and administration interval (half-life in hours, 24, 48 and 138; administration interval, weekly W or monthly M). N = 25.
Figure 7 Haemoglobin variability and epoetin dose adjustments in simulation B. Correlation between the number of therapy modifications
and Hb variability (expressed as delta Hb) in the maintenance phase. N = 25.
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nephrologists have been more careful and conservative
with prescriptions when faced with an administration
interval of 4 weeks. The result was that monthly admin-
istration has been translated into a significantly lower
average Hb value (10.3 vs. 11.1 g/dL; P < 0.01), as well
as a lower percentage of Hb values at the target of 11-
12 g/dL (18.4 vs. 26.8%; P < 0.05). Accordingly, with the
type of ESA and the administration interval mostly used
at the time the study was carried out, the only modality
that was characterised with a prescription ability (calcu-
lated by indexing the percentage of parameter values on
target, below target, above target, and above the safety
Hb value of 13 g/dL) that was statistically superior com-
pared to the others (primary end point) was the combi-
nation of the shortest half-life (24 hours) with weekly
administration (ability score 1.52 vs. 1.24; P < 0.05). The
smaller adjustments needed, regarding the mean ESA
dose, between the equilibration and maintenance phases
using the monthly administration interval (9.1 vs. 14.5%;
P < 0.05) was probably due to the lower mean Hb value
at the end of the equilibration phase when the monthly
interval was used; so it should not be interpreted as bet-
ter prescription ability but as more prudence when
faced with long half-lives.
As can be observed when comparing Figures 2 and 3,
the weekly Hb value shows larger variability when using
monthly compared to weekly administration (only the
monthly values as shown in Figure 2 were visible to the
prescriber). The greatest variability in the model is gener-
ated by red blood cell sub-populations of different ages
(a fact shown by the curve behaviour in Figure 3 as well
as by the significant difference in the fluctuation of red
blood cell lifespan during the simulation summarised in
Figure 8), caused by the single monthly dose of erythro-
poietin that has resulted in a non-homogeneous genera-
tion and elimination of red blood cells over time.
Hb variability analysis enables a critical evaluation of
the meaning of standard deviation (average distance of
individual values from the mean) compared to delta Hb
(average of the absolute value of the difference between
consecutive measurements). In the particular case of the
simulation, delta Hb is in fact the parameter that best
translates incidental changes in Hb values.
Using a monthly instead of a weekly administration
interval, the number of modifications to the erythropoie-
tin dose is significantly lower (4.9 vs. 8.2; P < 0.001). As
suggested in the literature [19] and demonstrated with
the significant direct correlation between Hb variability
and number of epoetin dose adjustements (Figure 7), this
fact could have favourable consequences on Hb stability.
Conclusions
In conclusion, bearing in mind the limitations of our
model, the results obtained with our simulator could be
used as a path for further experimental studies. An ESA
prescription simulator can be a useful educational tool
to raise awareness about the possible consequences of
changing the medication’s half-life or its administration
interval. The first time users were faced with an erythro-
poietin compound with a half-life of 138 hours and a
monthly administration interval, they were exposed to a
risk of overshooting, which was corrected by the train-
ing on the simulator. With respect to possible conse-
quences, very long half-lives and monthly administration
intervals translate into a conservative prescription that
maintains Hb values below the desired level. As a conse-
quence the shortest half-life (24 hours) with the weekly
administration interval is associated with the better pre-
scription ability. The monthly prescription interval how-
ever, as suggested in the literature, is accompanied by
less therapeutic adjustments; in this regard a direct cor-
relation between Hb variability and number of therapy
modifications has been demonstrated. In our simula-
tions, the delta Hb has proven to be a better tool for
evaluating intra-patient Hb variability than standard
deviation.
Computer-based simulation tools can be particularly
useful for improving prescription patterns and for testing
new working hypotheses such as determining the factors
that influence Hb variability. Additional knowledge on
the pharmacodynamic of ESAs is necessary to fine-tune
the models and bring them closer to the level of regular
clinical experience. However, the research of possible
consequences of half-life and administration interval for
ESAs that are currently marketed with respect to the Hb
stability will require specific targeted clinical trials.
Additional material
Additional File 1: The epoetin prescription simulator. Visual Basic
version on Excel of the pharmacokinetic simulation tool used in the
study.
Additional File 2: Appendix 1. Characteristics of the “Epoetin
Prescription Simulator” tool and user’s manual.
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